Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITI IV: Microplasmin in Acute Ischemic Stroke
NCT00123305Phase 2Completed
- Sponsor
- Oxurion
- Start
- Oct 2005
- Primary completion
- May 2008
- Modality
- Therapeutic Enzymes
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of ocriplasmin in ischemic stroke (4 arms), sponsored by Oxurion. Primary endpoints: Intracranial Haemorrhage at Day 7 and Change from Baseline in NIHSS at Day 90. Started Oct 2005; status: completed.
02
Drugs
ocriplasmin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00123305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00123305.